# American Healthcare REIT (AHR) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/AHR/thesis · /stocks/AHR/memo

## Financial Snapshot

---
step: 04
title: Financial Quality & Adversarial Sweep
ticker: AHR
company: American Healthcare REIT, Inc.
source: coverage-next-full
sector_track: REIT
created: 2026-06-08
---

### Step 04 — Financial Quality: American Healthcare REIT (AHR)

#### 1. Statement Quality Assessment

##### Income Statement Quality

AHR's income statement reflects the complexity of a RIDEA-heavy REIT: revenue includes full operating revenue of healthcare facilities (room charges, ancillary fees), while expenses include direct healthcare labor and supplies. This is economically correct under GAAP but makes margin comparisons vs. NNN peers misleading.

**Key adjustments needed:**
- **Depreciation (D&A, ~$290M FY2025):** Real estate depreciation is non-cash and economically overstated for well-maintained properties; standard add-back in NAREIT FFO
- **Gain/loss on real estate:** $66M gain in FY2025 from property dispositions — non-recurring; excluded from NFFO [S1]
- **Impairments:** Pre-IPO periods (FY2021–2023) contained property impairment charges; now diminished
- **Transaction costs:** M&A and capital transaction costs excluded from NFFO; ran ~$20–40M in IPO/follow-on years [S1]
- **SBC:** ~$25–30M annually; excluded from NFFO; relatively modest at <2% of revenue [S1]
- **Interest expense reduction:** FY2025 interest expense ~$155M (vs. $226M in FY2023) — structural improvement from debt paydown, not manipulation [S1]

**Accounting quality: GOOD.** GAAP-to-NFFO bridge is clean and well-disclosed. Management's NFFO reconciliation is comprehensive and consistent with NAREIT guidance.

##### Balance Sheet Quality

| Metric | FY2025 | FY2024 | FY2023 |
|--------|--------|--------|--------|
| Total Real Estate (gross) | ~$6.1B | ~$5.4B | ~$4.5B [S1] |
| Accumulated Depreciation | ~$(1.2B) | ~$(1.0B) | ~$(0.8B) [S1] |
| Goodwill | ~$550M | ~$550M | ~$550M [S1] |
| Total Assets | ~$6.1B | ~$5.2B | ~$4.5B [S1] |
| Total Debt (long-term) | ~$1.5B | ~$2.1B | ~$2.5B [S1] |
| Total Equity | ~$3.9B | ~$3.1B | ~$1.9B [S1] |
| Accumulated Deficit | ~$(1.4B) | ~$(1.5B) | ~$(1.5B) [S1] |

**Goodwill ($550M):** Arose primarily from the 2021 GAHR III/IV merger and Trilogy acquisition/internalization. Represents ~9% of total assets. Not being amortized (GAAP). Impairment risk is manageable given Trilogy's operational momentum. [Judgment — Medium confidence]

**Accumulated deficit ($1.4B):** A legacy of pre-IPO losses and large distribution payments that exceeded GAAP earnings (common for non-traded REITs pre-listing). Does not indicate balance sheet distress. Post-IPO equity issuances ($2.5B+ combined) have substantially rebuilt equity.

**Balance sheet quality: GOOD.** Leverage is conservative for a REIT at 3.0x Net Debt/EBITDA; liquidity of $1.14B (revolver + cash) provides ample coverage. Main risk: continued acquisition activity could re-lever the balance sheet.

##### Cash Flow Statement Quality

| Metric | FY2025 | FY2024 | FY2023 |
|--------|--------|--------|--------|
| Operating CF | ~$175M | $84M | $(35M) [S1] |
| Capex (maintenance + growth) | ~$(110M) | ~$(90M) | ~$(70M) [S1] |
| FCF | ~$65M | ~$(6M) | ~$(105M) [S1] |
| Distributions paid | ~$(165M) | ~$(120M) | ~$(100M) [S1] |

FCF inflected positive in FY2024–2025 post-IPO, validating the thesis that high interest costs were the primary earnings drag. The large distribution payments vs. FCF gap is typical for growth REITs paying dividends ahead of full operating stabilization.

**Cash flow quality: GOOD.** Operating CF growing rapidly; maintenance capex reasonable at ~5% of revenue. Growth capex ($950M+ in FY2025) funded from equity raises, not operating cash flow.

#### 2. Adversarial Research Sweep

*This section documents potential financial risks, short arguments, litigation, regulatory actions, and adverse public interest research discovered through web search. Note: no earnings transcript analysis was performed (coverage-next-full path).*

##### 2a. Short Interest & Short Reports

**Short interest:** No prominent active short reports found for AHR as of mid-2026. Short interest is relatively modest for a recently-listed REIT; the stock rose ~548% from IPO price to market cap peak [S2][S3].

No published short-seller research found targeting AHR-specific accounting concerns.

##### 2b. Regulatory/Legal Actions

**No material litigation or regulatory actions identified** from public filings review (10-K risk factors + 8-K material events). AHR disclosed the following items in FY2025 10-K risk factors [S1]:
- Routine regulatory compliance risks for healthcare facilities (CMS surveys, state licensing)
- Standard REIT-related tax and compliance risks
- No ongoing material SEC investigations or DOJ actions disclosed

**CMS enforcement risk:** SNF facilities are subject to CMS survey inspections; deficiency citations can lead to Immediate Jeopardy (IJ) findings that temporarily restrict admissions. Trilogy has had isolated IJ citations historically (common in SNF industry); no systemic enforcement pattern identified. [Judgment]

##### 2c. Related-Party / Governance Concerns

**Management internalization (2021):** The co-founders (Hanson, Prosky) received ~$131.7M in OP units to internalize management from the Griffin Capital advisory arrangement [S5]. This was a one-time transaction standard for non-traded REIT listings; the economic terms were disclosed in the 2024 prospectus.

**NorthStar Trilogy acquisition (Sep 2024):** AHR acquired NorthStar's 24% stake in Trilogy for ~$258M — a related-party transaction (NorthStar was a co-investor). The transaction was reviewed by the independent board committee and the price was disclosed as being based on an independent appraisal [S2][S5].

**Assessment:** No red flags. Both transactions are disclosed, arm's-length reviewed, and economically rational.

##### 2d. CEO Medical Leave

AHR disclosed on February 3, 2026 that CEO Jeff Hanson was placed on medical leave [S2]. Co-founder Danny Prosky stepped in as Interim CEO. Hanson co-founded the company; his absence creates management continuity uncertainty if the leave becomes permanent. The board has not disclosed any succession plan. This is a **moderate governance risk** that should be monitored.

##### 2e. Pre-IPO Non-Traded REIT History

AHR's predecessor entities were non-traded REITs (GAHR III and GAHR IV) — a structure associated with high upfront selling commissions (typically 7–10% of capital raised) paid to broker-dealers. These fees were borne by the original non-traded REIT investors and did not benefit the listed company. No ongoing liability to AHR [S1][S5].

##### 2f. Trilogy Consolidation Risk

The decision to consolidate Trilogy from NNN to full RIDEA (effectively operating the healthcare business) exposes AHR to labor, regulatory, and Medicare/Medicaid operational risks that a passive NNN landlord would not bear [S1]. This is the appropriate trade-off for the higher NOI, but it is a genuine source of operational complexity not present in MOB-focused or NNN-only peers.

##### 2g. Adversarial Summary

| Concern | Severity | Conclusion |
|---------|---------|-----------|
| Short reports / accounting fraud | NONE FOUND | Not a current concern |
| CMS regulatory actions | LOW | Standard industry exposure; no systemic pattern |
| Related-party transactions | LOW | Disclosed; independent review |
| CEO medical leave | MODERATE | Execution risk; monitor for permanence |
| Pre-IPO fee structure | NONE (legacy) | Past issue for original investors; not AHR liability |
| RIDEA operational risk | MODERATE | Appropriate trade-off; well-managed by Trilogy |

**Adversarial Sweep Conclusion: No material adverse findings. The company's financial statements appear to be a fair representation of operations. Key monitoring items: CEO succession and Trilogy operational execution.**

#### Assumption Register Updates

| # | Assumption | Type | Confidence |
|---|-----------|------|-----------|
| A-04-1 | Goodwill impairment risk is low given Trilogy operational momentum | Judgment | Medium |
| A-04-2 | No undisclosed litigation that would materially impair operations | Judgment | Medium-High |
| A-04-3 | CEO medical leave is temporary; Danny Prosky provides adequate continuity | Judgment | Medium |

#### Source Index

| ID | Source |
|----|--------|
| S1 | SEC EDGAR XBRL + 10-K FY2025, FY2024 |
| S2 | AHR investor presentations + Q1 2026 earnings release |
| S3 | StockAnalysis.com + Tavily research |
| S4 | NIC / industry data |
| S5 | SEC DEF 14A 2026 Proxy |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AHR/fundamental

## Navigation

- Overview: /stocks/AHR
- Financials (this page): /stocks/AHR/financials
- Thesis: /stocks/AHR/thesis
- Investment Memo: /stocks/AHR/memo
- Coverage universe: /stocks